MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation
Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.
Completion of this stage moves the initiative, announced in June 2026, from launch to an initial assessment of screening predictions. The predictions have not been experimentally validated and serve only as a starting point for evaluating potential follow-up research within MitoCareX’s small-molecule discovery programs.
“We believe that completing this first screening stage is an important step in translating our initiative with Boltz into research insights,” said David Palach, Chief Executive Officer of Nexentis. “We are focused on advancing proprietary discovery programs through disciplined, evidence-based decisions. These initial predictions give us a basis for planning next steps, and further validation will be essential to determining their significance.”
The initiative combines MitoCareX’s proprietary drug-discovery capabilities with Boltz’s AI models to identify potential small-molecule starting points for selected discovery programs. MitoCareX retains control over its discovery programs and any small-molecule candidates it advances through the initiative.
Further scientific assessment and validation will determine whether the preliminary predictions support advancing any program. No assurance can be given that any compound identified through the initiative will be advanced into preclinical or clinical development.
About MitoCareX Bio Ltd.
MitoCareX Bio Ltd., a wholly owned subsidiary of Nexentis Technologies Inc., is advancing a focused drug-discovery platform designed to translate multidisciplinary scientific capabilities into potential therapeutic candidates. By integrating biology, chemistry and computationally enabled research, MitoCareX supports ongoing research activities directed toward candidate identification and development within its drug-discovery efforts. https://mitocarexbio.com/
About Nexentis Technologies Inc.
Nexentis Technologies Inc. (NASDAQ: NXTS) owns 100% of MitoCareX Bio Ltd., a drug-discovery company. Additionally, Nexentis adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.
For additional details, please visit https://nexentistech.com/
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “could,” “potential” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the significance of the preliminary computational predictions from the initial screening stage under MitoCareX’s drug-discovery initiative with Boltz; the potential for further computational analysis, experimental investigation and validation of such predictions; the assessment of next research steps and follow-up research opportunities within MitoCareX’s small-molecule discovery programs; the potential identification and advancement of small-molecule starting points or candidates; and the potential contribution of the initiative to MitoCareX’s broader discovery strategy. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause the Company’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, market and other conditions; our history of losses, our need for additional capital to fund our operations and our potential inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the risk that computational or AI-generated predictions may not be confirmed by experimental testing or may not identify viable candidates; our dependence on third-party collaborators, including Boltz, and their technologies; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates, including our renewable energy investments; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of the Nasdaq Capital Market; and the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026, and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.
Investor Relations Contact:
Michal Efraty
michal@efraty.com
